Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 4, Pages 828-838
Publisher
Springer Nature
Online
2014-10-17
DOI
10.1038/leu.2014.305
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
- (2014) T. Placke et al. BLOOD
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- HighEVI1expression is associated withMLLrearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group
- (2013) Phoenix A. Ho et al. BRITISH JOURNAL OF HAEMATOLOGY
- Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB
- (2013) Hsu-Ping Kuo et al. CANCER CELL
- Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML
- (2013) K R Kampen et al. LEUKEMIA
- High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia
- (2013) V Grossmann et al. LEUKEMIA
- In Vivo Imaging Enables High Resolution Preclinical Trials on Patients’ Leukemia Cells Growing in Mice
- (2013) Nadia Terziyska et al. PLoS One
- JAK2/STAT5 Inhibition Circumvents Resistance to PI3K/mTOR Blockade: A Rationale for Cotargeting These Pathways in Metastatic Breast Cancer
- (2012) Adrian Britschgi et al. CANCER CELL
- MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
- (2012) A. B. Turke et al. CANCER RESEARCH
- Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma
- (2012) Z. Li et al. CLINICAL CANCER RESEARCH
- Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases
- (2012) Harald Polzer et al. EXPERIMENTAL HEMATOLOGY
- VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
- (2012) D. C. Koboldt et al. GENOME RESEARCH
- Clinical relevance of Ki67 gene expression analysis using formalin-fixed paraffin-embedded breast cancer specimens
- (2012) Satoko Yamamoto et al. Breast Cancer
- Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule
- (2011) H. Ehrhardt et al. BLOOD
- Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins
- (2011) A. Yoshimi et al. BLOOD
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
- (2010) N. Chapuis et al. CLINICAL CANCER RESEARCH
- Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads
- (2009) K. Ye et al. BIOINFORMATICS
- Fast and accurate short read alignment with Burrows-Wheeler transform
- (2009) H. Li et al. BIOINFORMATICS
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
- (2009) J. Tamburini et al. BLOOD
- Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients
- (2009) Folkward G. Wiesner et al. BREAST
- Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
- (2009) P Cao et al. BRITISH JOURNAL OF CANCER
- Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells
- (2009) Andrew L. Muranyi et al. EXPERIMENTAL HEMATOLOGY
- Targeted therapy in acute myeloid leukaemia: current status and future directions
- (2009) Camilla Stapnes et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Functional proteomic profiling of AML predicts response and survival
- (2008) S. M. Kornblau et al. BLOOD
- High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated
- (2008) S. Lugthart et al. BLOOD
- Small molecule inhibitors of WNT signaling effectively induce apoptosis in acute myeloid leukemia cells
- (2008) Katharina Salome Minke et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia
- (2008) Sampa Ghoshal (Gupta) et al. LEUKEMIA RESEARCH
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer
- (2008) B. A. Rabinovich et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started